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Although extended-spectrum beta-lactamases (ESBLs) hydrolyze cephalosporin antibiotics, some ESBL-
producing organisms are not resistant to all cephalosporins when tested in vitro. Some authors have suggested
that screening klebsiellae or Escherichia coli for ESBL production is not clinically necessary, and when most
recently surveyed the majority of American clinical microbiology laboratories did not make efforts to detect
ESBLs. We performed a prospective, multinational study of Klebsiella pneumoniae bacteremia and identified 10
patients who were treated for ESBL-producing K. pneumoniae bacteremia with cephalosporins and whose
infecting organisms were not resistant in vitro to the utilized cephalosporin. In addition, we reviewed 26 similar
cases of severe infections which had previously been reported. Of these 36 patients, 4 had to be excluded from
analysis. Of the remaining 32 patients, 100% (4 of 4) patients experienced clinical failure when MICs of the
cephalosporin used for treatment were in the intermediate range and 54% (15 of 28) experienced failure when
MICs of the cephalosporin used for treatment were in the susceptible range. Thus, it is clinically important to
detect ESBL production by klebsiellae or E. coli even when cephalosporin MICs are in the susceptible range
(< 8 mg/ml) and to report ESBL-producing organisms as resistant to aztreonam and all cephalosporins (with
the exception of cephamycins).
Over the last 15 years, numerous outbreaks of infection with
organisms producing extended-spectrum beta-lactamases
(ESBLs) have been observed worldwide (16). The advent of
ESBL producers has represented a great threat to the use of
many classes of antibiotics, particularly cephalosporins. It has
been well recognized that poor outcome occurs when patients
with serious infections due to ESBL-producing organisms are
treated with antibiotics to which the organism is frankly resis-
tant. The mortality rate in such patients is significantly higher
than in patients treated with antibiotics to which the organism
is susceptible (21) and has ranged from 42 to 100% (11, 14, 21).
In the majority of instances in which “inappropriate” therapy
was given, the therapy was ceftazidime for an ESBL-producing
organism for which MICs of ceftazidime were elevated (often
.256 mg/ml).
Much more controversy exists as to whether cephalosporin
therapy is appropriate for ESBL-producing organisms for
which cephalosporin MICs are in the susceptible range (4).
Such a scenario is relatively common—of 141 American iso-
lates of ESBL-producing Klebsiella pneumoniae examined by
Jacoby et al. (7), only 23% would have been reported as cefo-
taxime resistant when examined using the NCCLS breakpoints
existing at that time. In a recent study from Europe, of 91
ESBL-producing klebsiellae, just 36% were reported by their
referring clinical laboratories as cefotaxime resistant (1).
In a 1998 survey of 369 American clinical microbiology lab-
oratories, only 32% (117 of 369) reported performing tests to
detect ESBL production by Enterobacteriaceae (3). It was not
reported why these laboratories did not make efforts to detect
ESBLs. However, some authors have suggested that ESBL
screening is not likely to affect patient outcome and hence is
neither clinically necessary nor cost-effective for the laboratory
(4). The purpose of this study was to examine the outcome of
serious infections due to ESBL-producing organisms in pa-
tients who were treated with cephalosporins to which the or-
ganism was “susceptible” or “intermediate” in vitro.
MATERIALS AND METHODS
Patients. A prospective, observational study of consecutive patients with
K. pneumoniae bacteremia was performed in 12 hospitals in the United States,
Taiwan, Australia, South Africa, Turkey, Belgium, and Argentina. The study
period was 1 January 1996 to 31 December 1997. Patients older than 16 years of
age with blood cultures positive for K. pneumoniae were enrolled, and a 188-item
study form was completed. Patients were monitored for 1 month after the onset
of bacteremia to assess clinical outcome, including mortality. The study was
observational in that administration of antimicrobial agents, and other therapeu-
tic management, was controlled by the patient’s physician, not the investigators.
The infection leading to bacteremia was identified as pneumonia, urinary tract
infection, meningitis, peritonitis, or a primary bloodstream infection using Cen-
ters for Disease Control and Prevention definitions (6).
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Antibiotic susceptibility testing. The antibiotic susceptibility of each blood
culture isolate was determined at each study site by disk diffusion or automated
broth microdilution methods. The method of determining antibiotic susceptibil-
ity and ESBL production and the combination of antibiotic susceptibility results
reported to physicians was at the choice of individual laboratories. Each isolate
was frozen at 280°C. At the conclusion of the study the stored isolates were sent
to a central study laboratory in Pittsburgh. There, the identity of each isolate as
K. pneumoniae was confirmed using standard methods (9). MICs of cefotaxime,
ceftriaxone, ceftazidime, cefepime, cefotetan, and cefoxitin were determined for
each isolate by Etest methodology (AB Biodisk, Solna, Sweden). The MICs
which were considered to indicate susceptibility were #8 mg/ml for cefepime,
cefotaxime, cefoxitin, ceftazidime, ceftizoxime, and ceftriaxone and #16 mg/ml
for cefotetan. MICs of 16 to 32 mg/ml for cefotaxime, ceftizoxime, or ceftriaxone,
16 mg/ml for ceftazidime, cefepime, and cefoxitin, and 32 mg/ml for cefotetan
were interpreted as intermediate results.
ESBL production was phenotypically determined at the central study labora-
tory by broth dilution using NCCLS performance standards, current as of Jan-
uary 2000 (12). In brief, the MICs for K. pneumoniae isolates of cefotaxime and
ceftazidime alone and in combination with 4 mg of clavulanic acid/ml were
determined. A decrease of three or more twofold concentrations in an MIC for
either cefotaxime or ceftazidime tested in combination with clavulanic acid
compared to its MIC when tested alone was considered phenotypic confirmation
of ESBL production.
Inclusion criteria and definition of failure of therapy. Patients receiving ceph-
alosporins (to which their ESBL-producing organism had tested susceptible or
intermediate using NCCLS definitions [12]) as therapy within the first 5 days
after onset of bacteremia were included in this analysis. In addition to these
cases, an additional case of bacteremic infection with ESBL-producing K. pneu-
moniae occurring at one of the participating institutions shortly after the con-
clusion of the study is reported separately in this paper.
Failure of antibiotic therapy was defined as death of the patient within 14 days
of the blood yielding a positive culture being drawn or persistence of fever or
bacteremia despite 48 h of cephalosporin usage.
Genotypic analysis. The genotypic relationships of ESBL-producing isolates
were determined by using pulsed-field gel electrophoresis (PFGE). The K. pneu-
moniae isolates were grown on blood agar plates for 16 h at 37°C. Genomic DNA
was prepared as previously described (9). Overnight digestion was performed
with 30 U of the restriction endonuclease XbaI (New England Biolabs, Beverly,
Mass.). PFGE was performed using a CHEF-DRII system (Bio-Rad, Hercules,
Calif.). The DNA was electrophoresed for 22 h at 14°C in a 1% agarose gel at 6
V/cm with a linear gradient pulse time of 5 to 35 s. Bacteriophage lambda
concatemers (48.5 kb; New England Biolabs) were used as molecular weight
standards. Gels were stained with ethidium bromide and photographed under
UV illumination; interpretation was done according to the criteria of Tenover et
al. (24).
Characterization of beta-lactamases. Beta-lactamases were liberated from K.
pneumoniae isolates by the use of lysozyme. Initial characterization of the beta-
lactamases was performed by analytical isoelectric focusing using a modification
of the method of Vecoli et al. (27). Briefly, 10 ml of crude beta-lactamase extract
was loaded onto a precast gel (Ampholine PAG plate; Pharmacia, Uppsala,
Sweden); running conditions were 200 V, 30 mA, and a constant power of 8 W.
Isoelectric focusing was usually completed within 2 h. Isolates with previously
characterized beta-lactamases (TEM-1, TEM-2, TEM-12, K-1, SHV-1, P99, and
ACT-1) (kindly provided by P. Bradford, Wyeth Ayerst Pharmaceuticals, Pearl
River, N.Y.) were used as controls. Beta-lactamase detection was performed by
overlaying the gel with nitrocefin-soaked filter paper.
Review of the literature. Treatment of all previously reported cases of serious
infection (defined as bacteremia, meningitis, peritonitis, or nosocomial pneumo-
nia) with ESBL-producing K. pneumoniae, Klebsiella oxytoca, or Escherichia coli
was also reviewed. These cases were identified by a MEDLINE search using the
key words “extended-spectrum beta-lactamase.” The references of the retrieved
articles were perused to find further reported cases. The abstracts of the pro-
grams of the Interscience Conference on Antimicrobial Agents and Chemother-
apy (1990 to 1999) were also reviewed for further cases.
RESULTS
A total of 455 episodes of K. pneumoniae bacteremia were
prospectively studied in 440 patients. Of these, 18.7% (85 of
455) episodes were due to ESBL producers and 81.1% (369 of
455) were due to non-ESBL producers. One additional episode
involved an isolate for which the MICs of the oxyimino beta-
lactam antibiotics were markedly elevated but no diminution
of MICs with the addition of clavulanic acid was observed.
MICs of cephamycin antibiotics for this isolate were in the
resistant range, and the organism most likely possessed an
AmpC-like enzyme. This episode was excluded from further
analysis.
The percentage of ESBL-producing isolates which were sus-
ceptible (S), intermediate (I), or resistant (R) to cephalospo-
rins (using the definitions above) were as follows: for cefotetan,
95.8% S, 2.8% I, and 1.4% R; for cefoxitin, 80.6% S, 9.7% I,
and 9.7% R; for cefepime, 79.2% S, 4.2% I, and 16.7% R; for
cefotaxime, 48.6% S, 29.2% I, and 22.2% R; for ceftriaxone,
36.1% S, 32.0% I, and 31.9% R; and for ceftazidime, 19.4% S,
8.3% I, and 72.2% R. Further details of the in vitro suscepti-
bilities of the ESBL-producing strains are given in Table 1.
Six patients with an ESBL-producing strain were treated
with a cephalosporin active in vitro; that is, one for which the
MIC was #8 mg/ml. These patients received ceftriaxone (two
patients), cefepime (two patients), cefotaxime (one patient),
and ceftazidime (one patient). Two of these six patients died,
and a further patient had continued fevers despite 72 h of
cephalosporin therapy; these fevers resolved after therapy was
changed to meropenem. The remaining three patients were
cured of their infection with cephalosporin therapy. One of
these patients had a repeat episode of bacteremia with ESBL-
TABLE 1. In vitro susceptibilities of ESBL-producing K. pneumoniae bloodstream isolates to cephalosporins
Antibiotic
% of isolates (cumulative %) for which the MIC (mg/ml) was:
#1 2 4 8 16 32 $64
True cephalosporins
Cefotaxime 5.6 (5.6) 18.1 (23.6) 5.6 (29.2) 19.4 (48.6) 13.9 (62.5) 15.3 (77.8) 22.2 (100)
Ceftriaxone 4.2 (4.2) 5.6 (9.7) 15.3 (25.0) 11.1 (36.1) 16.7 (52.8) 15.3 (68.1) 31.9 (100)
Ceftazidime 4.2 (4.2) 4.2 (8.3) 5.6 (13.9) 5.6 (19.4) 8.3 (27.8) 5.6 (33.3) 66.5 (100)
Cefepime 23.6 (23.6) 22.2 (45.8) 23.6 (69.4) 9.7 (79.2) 4.2 (83.3) 9.7 (93.1) 6.9 (100)
Cephamycins
Cefoxitin 0 (0) 2.8 (2.8) 59.7 (62.5) 18.1 (80.6) 9.7 (90.3) 4.2 (94.4) 5.6 (100)
Cefotetan 65.3 (65.3) 19.4 (84.7) 8.3 (93.1) 1.4 (94.4) 1.4 (95.8) 2.8 (98.6) 1.4 (100)
The interpretation of MICs (in micrograms per milliliter) of cephalosporin antibiotics against klebsiellae and E. coli is as follows: for cefotaxime and ceftriaxone,
susceptible, #8, intermediate, 16 to 32, and resistant, $64; for ceftazidime, cefepime, and cefoxitin, susceptible, #8, intermediate, 16, and resistant, $32; and for
cefotetan, susceptible, #16, intermediate, 32, and resistant, $64.
VOL. 39, 2001 CEPHALOSPORINS FOR ESBLs? 2207
 o
n
 O
ctober 22, 2015 by University of Queensland Library
http://jcm.asm.org/
D
ow
nloaded from
 
producing K. pneumoniae after ceftriaxone monotherapy, but
PFGE showed that the strains were not genotypically related.
A further three patients were treated with a cephalosporin,
the MIC for which was in the intermediate range (16 to 32
mg/ml for cefotaxime and ceftriaxone and 16 mg/ml for cefta-
zidime). One of these patients died, and the two others re-
quired a change in therapy because of continued evidence of
infection. These two patients were ultimately cured of their
infection.
The clinical details of these nine patients and an additional
patient from one of the participating hospitals are summarized
in Table 2. The clinical details of 26 patients previously re-
ported (2, 4, 8, 15, 17, 18, 19, 21, 22, 23, 28) are reported in
Table 3. When the data for the 10 patients from the interna-
tional K. pneumoniae bacteremia study were combined with
those for the 26 previously reported patients, data for a total of
36 patients were available for analysis. Of the cases, 83% (30 of
36) were bacteremia; the remainder were nosocomial pneumo-
nia (3 cases), empyema (1 case), peritonitis (1 case), and men-
ingitis (1 case). The ESBL-producing organisms included K.
pneumoniae (26 cases), E. coli (7 cases), K. oxytoca (2 cases),
and mixed K. pneumoniae and E. coli (1 case). The cephalo-
sporins which were used in these 36 cases of infection were
cefotaxime or ceftriaxone (19 cases), ceftizoxime (6 cases),
cefepime (6 cases), ceftazidime (3 cases), cefmetazole (1 case),
and cefoxitin (1 case). The cases treated with cefoxitin and
cefmetazole (cephamycins) were excluded from further analy-
sis, since the cephamycins are resistant to the hydrolytic activity
of ESBLs. Additionally, two patients who died within 48 h of
commencing cephalosporin therapy were also excluded from
further analysis.
Of the remaining 32 patients, 54% (15 of 28) had clinical
failure while receiving a cephalosporin to which the organism
was susceptible, and 100% (4 of 4) had clinical failure while
receiving a cephalosporin to which the organism was interme-
diate. Four of the 15 patients with clinical failure with cepha-
losporins to which the organism was “susceptible” died within
14 days of beginning the cephalosporin treatment; of the 11
remaining patients with clinical failure, all were cured with a
change in antibiotic therapy. The change was to a carbapenem
in all cases except one.
Of patients with organisms which were “susceptible” to the
cephalosporin used, clinical failure was observed in 9 of 16
patients receiving cefotaxime or ceftriaxone, 4 of 5 receiving
cefepime, 2 of 6 receiving ceftizoxime, and 0 of 1 receiving
ceftazidime (Tables 2 and 3). There was no relationship be-
tween the number of beta-lactamases present in the infecting
organism and likelihood of failing cephalosporin therapy: 5 of
10 patients whose infecting organism had one beta-lactamase
failed, compared to 5 of 12 whose infecting organism had two
beta-lactamases (P . 0.20).
Further breakdown of clinical failure by MIC is given in
Table 4 for the 23 patients for whose isolates a precise MIC
was recorded. Failure rates were highest (100% [6 of 6]) in
patients with infecting organisms for which the MIC of the
cephalosporin used was 8 mg/ml and lowest in patients (27% [3
of 11]) with infecting organisms for which the MIC was ,2
mg/ml; there was a statistically significant increase in failure
rate as MICs rose within the susceptible range (P 5 0.004).
DISCUSSION
The NCCLS established breakpoints for expanded-spectrum
cephalosporin antibiotics shortly after the clinical release of
these antibiotics in the early 1980s. Correlations of MICs to
clinical outcome were excellent; indeed, an MIC of #8 mg/ml
correlated with $92% clinical success for all relevant species,
including K. pneumoniae and E. coli (R. Jones, personal com-
munication). It is important to note that these breakpoints
were established essentially prior to the era of the ESBLs.
In the late 1980s and early 1990s, it was recognized that
MICs of some cephalosporins for isolates possessing ESBLs
may be #8 mg/ml (that is, in the susceptible range). Brun-
Buisson et al. (2) in a description of the first large outbreak of
ESBL-producing organisms reported that the ceftriaxone and
cefotaxime MICs for some ESBL-producing strains were 0.5 to
4 mg/ml. Although these cephalosporin MICs were in the sus-
ceptible range, they were substantially higher than the MICs
for non-ESBL-producing strains at their hospital (ceftriaxone
MICs, 0.03 to 0.06 mg/ml). Good clinical outcomes were ob-
served when expanded-spectrum cephalosporins were used to
treat urinary tract infections due to ESBL-producing organ-
isms, but the outcome when serious infections were tackled
was questionable.
Initial challenges to the notion that ESBL-producing organ-
isms for which MICs of expanded-spectrum cephalosporins are
in the susceptible range may not be truly susceptible (when
serious infections are considered) came from in vitro studies of
“inoculum effect” and animal studies. In vitro, the MICs of
cephalosporins rise as the inoculum of ESBL-producing organ-
isms increases (10, 20, 26). For example, for a K. pneumoniae
strain producing TEM-26, at an inoculum of 105 CFU/ml the
cefotaxime MIC was 0.25 mg/ml and the cefepime MIC was 1
mg/ml, but when the inoculum rose to 107 CFU/ml, the MICs
rose to 64 and .64 mg/ml, respectively (26). Experience in
experimental animal models of infection with ESBL-producing
organisms has demonstrated failure when ceftriaxone or cefo-
taxime was used, despite levels of antibiotics in serum far
exceeding the MIC of the antibiotic when tested at the con-
ventional inoculum of 105 organisms per ml (5, 20).
In view of the in vitro data and animal data presented above,
combined with case reports of failure of cephalosporin therapy
in serious infections due to ESBL-producing strains (even in
the presence of apparent susceptibility to cephalosporins), the
NCCLS Subcommittee on Antimicrobial Susceptibility Testing
convened a working party on detection of ESBLs in the late
1990s. The conclusions of this working party were that strains
of clinical isolates of Klebsiella spp. and E. coli should be
screened for ESBL production and that isolates suspected of
ESBL production should be subjected to a phenotypic confir-
matory test. These conclusions are part of the Approved Stan-
dard for Methods for Dilution Antimicrobial Susceptibility Tests
published in January 2000 (12). In brief, MICs of $2 mg/ml for
cefpodoxime, ceftazidime, aztreonam, cefotaxime, or ceftriax-
one should be regarded as possibly indicating ESBL produc-
tion. The phenotypic confirmatory test should be performed on
suspicious isolates and consists of testing the MIC of cefo-
taxime and ceftazidime combined with clavulanic acid. A de-
crease in an MIC of three or more twofold concentrations for
either antibiotic when tested in combination with clavulanic
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acid compared to its MIC when tested alone indicates the
presence of an ESBL. Similar guidelines are available for an-
timicrobial disk susceptibility testing (13). The NCCLS recom-
mends that for all ESBL-producing strains, the test result
should be reported as resistant for all penicillins, cephalospo-
rins, and aztreonam (12, 13).
In the past, anecdotal reports have been published in which
patients have had good clinical outcomes despite receiving
cephalosporins as treatment of infections with ESBL-produc-
ing organisms, and such occurrences have been used as an
argument against routine screening for ESBL production (4).
However, when the results of our study were combined with
previously published reports, we found that 54% (15 of 28) of
patients treated with cephalosporins for serious infections due
to ESBL-producing organisms for which the cephalosporin
MIC was in the “susceptible” range experienced failure of this
therapy. All patients with therapeutic failure either died or had
continued signs of infection which necessitated a change in
antibiotic therapy. Outcome was worst for patients in whom
the cephalosporin MIC of the infecting organism was 8 mg/ml;
all six of these patients experienced failure of this therapy, and
two of them died. Such data are consistent with recommenda-
tions that ESBL-producing organisms be reported as resistant
to all cephalosporins.
However, there appears to be a marked discrepancy between
these clinical data and the recently reported inability (or un-
willingness) of clinical microbiology laboratories to detect
ESBL-producing organisms. Tenover et al. (25) sent three
ESBL-producing organisms to 38 clinical microbiology labora-
tories in Connecticut for antimicrobial susceptibility testing;
fewer than 10% of laboratories reported isolates possessing the
ESBLs SHV-8 and SHV-4 as resistant to cefotaxime. In a large
survey of 369 American clinical microbiology laboratories, just
32% (117 of 369) reported performing tests to detect ESBL
production by Enterobacteriaceae. We believe that clinicians,
whose laboratories do not perform tests for detection of ES-
BLs and do not report ESBL producers as resistant to cepha-
losporins, risk poor outcome for their patients with serious
infections with ESBL producers.
There are several reports of urinary tract infections due to
ESBL-producing organisms being successfully treated with
cephalosporins, regardless of the results of in vitro suscep-
tibility tests (2, 4, 11). This raises the question of whether
clinical microbiology laboratories should test urinary tract
isolates for the presence of ESBLs. There are not sufficient
data in the literature regarding treatment of such less seri-
ous infections to determine if the presence of ESBLs in such
settings has clinical significance. However, the detection of
ESBLs in any clinical isolate has great potential significance
from the point of view of infection control. More than 50
outbreaks of infection with ESBL-producing organisms have
been reported thus far (16), and almost all indicate hori-
zontal transfer of ESBL-producing strains. Such outbreaks
have been curtailed by prompt introduction of infection
control procedures or changes in antibiotic usage patterns
(16). Therefore, we recommend that (i) laboratories screen
all clinical isolates of klebsiellae and E. coli (regardless of
the severity of clinical illness or site of infection) for the
presence of elevated MICs or reduced zone diameters pos-
sibly indicating ESBLs and (ii) if ESBL production is con-
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firmed, either infection control practitioners be notified or a
comment appear on the laboratory report indicating the
epidemiological significance of ESBL production.
MICs of some cephalosporins for a small number of ESBL-
producing isolates will be #1 mg/ml. In this study we reviewed
11 cases of serious infections due to ESBL producers for which
the MIC of the antibiotic which was used to treat the infection
was #1 mg/ml. Death occurred in 18% (2 of 11) of these
patients, and 9% (1 of 11) required a change in therapy to
effect cure (Tables 2 to 4). The number of patients in this
category is too small to accurately state whether cephalospo-
rins can be reliably used in this setting.
The cephamycins (cefoxitin, cefotetan, and cefmetazole) are
structurally different from the “true” cephalosporins and have
enhanced stability to ESBLs. More than 90% of ESBL-pro-
ducing organisms were “susceptible” to cephamycins (Table 1).
However, there are only two reports in peer-reviewed litera-
ture of the use of cephamycins for the treatment of serious
infections with ESBL-producing organisms (15, 22). In one
case, relapse of infection occurred with a cefoxitin-resistant
strain (15). Of the five patients evaluated in this report who
were treated with cefepime, four experienced clinical failure.
Further clinical experience with cephamycins and cefepime
needs to be published in order to more fully evaluate the
potential usefulness of these antibiotics against serious infec-
tions due to ESBL producers.
In summary, we have documented that suboptimal clinical
outcome occurs when cephalosporins are used for the treat-
ment of serious infections due to ESBL-producing organisms
which may appear to be susceptible on the basis of cephalo-
sporin MICs of 2 to 8 mg/ml. Clinical microbiology laboratories
should take heed of current recommendations for detection of
ESBLs in order to avoid potential treatment failure when
cephalosporins are used.
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